Free Trial
→ Trump’s national nightmare is here (From Porter & Company) (Ad)tc pixel

EKF Diagnostics (LON:EKF) Posts Quarterly Earnings Results

Written by MarketBeat
September 17, 2025
EKF Diagnostics logo with Medical background

Key Points

  • EKF Diagnostics reported a quarterly earnings per share (EPS) of GBX 0.43, with a net margin of 9.37% and a return on equity of 7.03%.
  • The company's stock opened at GBX 29, boasting a market capitalization of £130.24 million and a high price-to-earnings ratio of 2,101.45.
  • EKF specializes in Point-of-Care analysers for Hematology and Diabetes, and offers life sciences services including the manufacture of enzymes for diagnostic applications.
  • MarketBeat previews top five stocks to own in October.

EKF Diagnostics (LON:EKF - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported GBX 0.43 earnings per share (EPS) for the quarter, Digital Look Earnings reports. EKF Diagnostics had a net margin of 9.37% and a return on equity of 7.03%.

EKF Diagnostics Price Performance

Shares of LON:EKF opened at GBX 29 on Tuesday. The company has a market cap of £130.24 million, a price-to-earnings ratio of 2,101.45 and a beta of 0.57. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.60 and a quick ratio of 1.77. The firm has a 50 day simple moving average of GBX 28.46 and a 200 day simple moving average of GBX 25. EKF Diagnostics has a one year low of GBX 18.40 and a one year high of GBX 32.

EKF Diagnostics Company Profile

(Get Free Report)

EKF is an AIM-listed global diagnostics business focussed on: ● Point-of-Care analysers in the key areas of Hematology and Diabetes ● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications. EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in EKF Diagnostics Right Now?

Before you consider EKF Diagnostics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EKF Diagnostics wasn't on the list.

While EKF Diagnostics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.